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Progress in the detection and treatment of cancer has led to an impressive reduction in both mortality and morbidity. Due to their mech-
anism of action, however, conventional chemotherapeutics and some of the newer anti-cancer signaling inhibitors carry a substantial risk of
cardiovascular side effects that include cardiac dysfunction and heart failure, arterial hypertension, vasospastic and thromboembolic ischae-
mia, dysrhythmia, and QT prolongation. While some of these side effects are irreversible and cause progressive cardiovascular disease,
others induce only temporary dysfunction with no apparent long-term sequelae for the patient. The challenge for the cardiovascular spe-
cialist is to balance the need for life-saving cancer treatment with the assessment of risk from cancer drug-associated cardiovascular side
effects to prevent long-term damage. This review discusses concepts for timely diagnosis, intervention, and surveillance of cancer patients
undergoing treatment, and provides approaches to clinical uncertainties.
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Introduction
New treatment modalities in oncology and haematology have
improved the prognosis of patients with malignancies.1 An import-
ant factor of this progress was the introduction of signalling inhibi-
tors, which are now used either as monotherapy or in combination
with conventional chemotherapy (Table 1). However, many of
these new drugs also interact with cardiovascular signalling and
have important side effects, particularly during times of increased
cardiac stress. The cardiovascular system has limited variability in
response to these iatrogenic effects, and the correct management
may be crucial to ultimately improve longevity and quality of life for
cancer patients. Table 2 provides an overview of clinically relevant
cardiovascular side effects associated with some more-commonly
used anti-cancer agents.
The present review addresses cardiotoxicity in a different light,
in that it does not attempt to provide a mere listing of frequent and
infrequent adverse events but strives to provide the cardiologist
with insight to appreciate the differences with which the heart
can react, and how those differences affect our approach to
these patients; more formal listings may be found in other
sources.2 We discuss concepts for timely diagnosis, intervention,
and surveillance. Where necessary, and when strong data are
not available, we provide approaches to clinical uncertainties, and
in that regard, this review represents a perspective that is continu-
ally evolving as new data are presented. The vital balance of accept-
ing temporary cardiovascular side effects so as not to impede a
patient’s ability to benefit from cancer treatment is a fundamental
component of a new discipline now often referred to as
Cardio-Oncology or Onco-Cardiology.
Non-reversible or reversible: a cardinal
distinction
Historically, non-reversible cardiovascular side effects that eventu-
ally led to progressive cardiac disease were the consequence of
some oncologic therapies; a prime example being anthracycline-
induced cardiotoxicity leading to progressive systolic heart
failure.3 With the introduction of new cancer drugs, such as signal-
ling inhibitors, a new phenomenon has been observed; cardiac dys-
function that resolves for most patients over time. In an effort to
classify cardiotoxicity of cancer drugs, Ewer et al.4 proposed a
system to identify drugs that have the potential to cause irrevers-
ible damage (Type I) vs. drugs that predominantly induce reversible
dysfunction (Type II) (Figure 1). However, this classification system
does have limitations; for example, trastuzumab, a Type II drug, can
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Table 1 Systemic cancer drugs with important cardiovascular side effects; selected indications
Class/drug Selected indications Important CV side effects
Cytostatic chemotherapeutics Anthracyclines/analogues
Doxorubicin Lymphoma Cardiac dysfunction/heart failure
Daunorubicin Leukaemia
Epirubicin Breast cancer
Ovarian cancer
Sarcoma
Mitoxantrone Leukaemia
Multiple sclerosis
Pyrimidine analogues
Fluorouracil (5-FU) Colorectal cancer Coronary spasms/ischaemia
Capecitabine Breast cancer
Alkylating agents
Cyclophosphamide Breast cancer Myocardiatis (rare)
Cisplatin Genitourinary cancer Thrombosis
Antimicrotubule agents
Paclitaxel Breast cancer Bradycardia
Colorectal cancer
Signalling inhibitors Anti-HER2
Trastuzumab Breast cancer Cardiac dysfunction
Lapatinib Gastric cancer
Angiogenesis inhibitors/anti-VEGF
Bevacizumab Gastrointestinal cancer Hypertension
Sunitinib Renal cell carcinoma Endovascular damage
Sorafenib Hepatocellular carcinoma
BCR-ABL inhibitors
Imatinib Leukaemia Oedema, cardiac dysfunction
(rare)
Dasatinib Gastric cancer QTc prolongation
Nilotinib
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Table 2 Summary of cardiovascular side effects of selected cancer therapeutics
Cardiac response Drug Frequency Mechanism Reversibility
Contractile dysfunction/heart failure Anthracyclines Cumulative dose-related Myocyte death Minimal
Cyclophosphamide Rare Myocarditis Partial
Cisplatin Rare Unknown Unknown
Trastuzumab Variablea Contractile protein dysfunction High
Lapatinib Reported
Bevacizumab Low Hypertension? Reported
Sunitinib Low Mitochondrial dysfunction Partial
Sorafenib Rare Unknown
Imatinib Rare Mitochondrial dysfunction High
Arterial hypertension All angiogenesis inhibitors Moderate, dose-dependent Endothelial dysfunction Unknown
Myocardial ischaemia Pyrimidine analogues Moderate Direct vasospasm High, unless infarction
Thomboembolism Cisplatin Moderate Endothelial dysfunction Variable
All angiogenesis inhibitors Moderate Endothelial dysfunction Variable
Arrhythmia/QT prolongation Arsenic trioxide Moderate HERG K+ blockage High
Lapatinib Rare HERG K+ blockage Unknown
Sunitinb Rare HERG K+ blockage Unknown
Nolitinib Rare HERG K+ blockage Unknown
Dasatinib Rare HERG K+ blockage Unknown
aFrequently in combination with anthracyclines.
Cancer drugs and the heart 1103
trigger irreversible cardiac damage in patients with severe pre-
existing cardiac disease, or potentiate anthracycline Type I cardio-
toxicity.5 For cardiovascular side effects from other modern cancer
therapeutics, such as angiogenesis inhibitors-induced arterial
hypertension and nephrotoxicity, the reversibility remains
unknown.
Cardiac dysfunction and heart
failure
Cardiac dysfunction and heart failure are among the most
serious cardiovascular side effects of systemic cancer treatment.
Conventional chemotherapeutics, such as anthracyclines, anti-
metabolites, and cyclophosphamide, can induce permanent myo-
cardial cell injury—albeit by diverse mechanisms—and by cardiac
remodelling.6 Signalling inhibitors currently in use, like human epi-
dermal growth factor receptor 2 (HER2/erbB2) and angiogenesis
inhibitors, predominantly affect cardiac metabolism and contractile
proteins, leading to transient contractile dysfunction. Understand-
ing the mechanistic pathophysiology of cancer drug-associated
cardiac dysfunction is important to predict, treat, and prevent
these side effects, although it can be challenging to identify the
proper mechanism in individual patients.
Anthracyclines and agents with
cumulative dose-related cardiotoxicity
(Type I agents)
Anthracyclines and the non-anthracycline analogue mitoxantrone
(Table 1) are among the most effective antitumor agents;
however, their use is compromised by cardiotoxicity, which has
been the subject of considerable attention over the past 35
years.7 Data from endomyocardial biopsy and troponin I measure-
ments suggest that myocyte injury may occur during or early after
anthracycline exposure. However, due to substantial cardiac
reserves and the activation of compensatory mechanisms, clinical
manifestation may not become apparent until months to years
after the initial chemotherapy exposure (Figure 2).8,9
Clinically, early cardiac side effects are typically reversible and
self-limiting and include dysrhythmia, repolarization changes in
the electrocardiogram, pericarditis, and less frequently myocarditis
(Table 3). It remains uncertain whether patients who experience
these early cardiac side effects are also more likely to develop
Figure 1 Depiction of the fundamental differences between non-reversible damage (type I) and reversible dysfunction (type II). Non-revers-
ible damage is associated with cell loss, resulting in an injury that is cumulative dose-related and irreversible at the cellular level. Reversible
dysfunction may result in disarray of the contractile elements, a phenomenon that has a much greater likelihood to undergo functional recovery.
Risk factors and other cancer therapy may influence the expression of both forms of injury, while cardiovascular therapy may delay or prevent
the ultimate expression of functional cardiac dysfunction.
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late anthracycline cardiotoxicity, a condition that leads to cardio-
myopathy and systolic heart failure. Patients treated with anthracy-
clines are five times more likely to develop chronic heart failure or
reduced left ventricular ejection fraction (LVEF) compared with
those treated with a non-anthracycline-containing chemother-
apy.10 The incidence of anthracycline-induced cardiotoxicity is
dose-dependent. Patients with no other risk factors usually toler-
ate cumulative doses of doxorubicin of up to 300 mg/m2 (equiva-
lent to 550 mg/m2 of epirubicin) quite well, with a rate of heart
failure of less than 2%.11 Above this dosage, the rates of cardiotoxi-
city rise exponentially. However, there is significant inter-individual
heterogeneity; patients over 65 years of age and children may
develop toxicity at lower cumulative dosages.11,12 Other factors
that seem to influence sensitivity to anthracycline-induced cardio-
toxicity include genetic predisposition, arterial hypertension, previ-
ous or concurrent mediastinal radiation therapy, and combination
with alkylating or antimicrotubule chemotherapeutics; many other
risk factors have been studied, and from a practical standpoint we
may assume that any insult that has previously damaged (i.e.
depleted reserves) or any factor that makes the heart more sus-
ceptible to ongoing or future damage should be considered a po-
tential risk factor for anthracycline cardiotoxicity. It should be
noted, however, that those risk factors that have been studied
have had a relatively short follow-up period and long-term investi-
gations are needed to better assess the true impact of risk factors
for anthracycline cardiotoxicity.3
The mechanism of anthracycline-induced cardiotoxicity is
complex and not fully understood. The drug must enter myocytes
to cause damage. Once inside the cell, anthracyclines form reactive
oxygen species through iron-complex formation and cause mito-
chondrial dysfunction with consecutive changes in calcium homeo-
stasis and contractile function. This also explains why one of the
first manifestations of anthracycline cardiotoxicity is diastolic dys-
function—a finding with unknown prognostic significance.13
Further increase in myocardial anthracycline concentration
induces myocyte cell death either by apoptosis or necrosis, a crit-
ical factor for long-term cardiovascular prognosis. Quantitative
methods of assessing myocardial injury, such as right ventricular
biopsies or cardiac biomarkers, can therefore have a prognostic
value.8,14
Several methods were investigated to reduce anthracycline car-
diotoxicity, including pharmacokinetic modification by liposomal
encapsulation, alteration of chemical structure leading to drugs
such as epirubicin, altering drug-infusion regimens to decrease
peak plasma levels, and attenuation of iron chelation through pre-
treatment with dexrazoxane.15–18 Most of these methods have
been associated with a reduction in cardiovascular events in
anthracycline-treated patients; however, except for the use of epir-
ubicin, most of these strategies are not in common practice in the
clinical setting. Other approaches to mitigate the cardiotoxic
impact of anthracyclines employ potentially cardioprotective med-
ications, such as angiotensin-converting enzyme (ACE) inhibitors.19
Although promising data have been published recently, convincing
evidence from large randomized and prospective trials is still
needed.
Other agents with myocyte destruction
Any cancer drug that may lead to myocyte injury or destruction
can induce irreversible cardiotoxicity. For example mitoxantrone,
an anthracycline analogue, can result in cardiotoxicity that is not
clinically different from the cardiac damage caused by true anthra-
cyclines.20 Cyclophosphamide can cause haemorrhagic cell necro-
sis that is more common with larger single doses, and may lead to
Table 3 Key facts: anthracycline-induced
cardiotoxicity
Anthracycline cardiotoxicity
Injury may result in myocyte death; irreversible
Risk factors
Cumulative dose
Pre-existing heart disease
Age (young children and .65 years)
Mediastinal radiation
Combination chemotherapy
Systolic heart failure
Typically months to years after exposure
Individual variation (genetic predisposition)
Cardioprotective strategies
Altered anthracycline structure (Epirubicin)
Altered delivery systems (liposomal preparations)
Schedule modification (24–96 h continuous infusion instead
of bolus)
Cardioprotective agents (dexrazoxane)
Cardiac medications (only single-centre experience)
Angiotensin-converting enzyme inhibitors
Figure 2 Graphic representation of the temporal relation
between the administration of a cardiotoxic agent (e.g. anthracy-
clines) and the development of contractile dysfunction. Exposure
to chemotherapeutic agents can induce myocardial oxidative
stress and provoke dose-dependent cardiac cell loss. Activation
of cardiac compensatory mechanisms including survival factors,
may delay cardiac dysfunction typically for years. However, ex-
haustion of these mechanisms and additional stress factors,
such as hypertension and coronary artery disease eventually
lead to progression of disease and cardiac dysfunction.
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severe heart failure or death. However, with the lower cycle doses
presently used, these toxicities are seen infrequently.21 Cisplatin
has also been associated with late-onset cardiac dysfunction, al-
though the cardiovascular side effects appear less severe than
those of anthracyclines.22 Finally, myocardial ischaemia induced
by pyrimidine analogues infrequently leads to myocardial infarction
with all long-term cardiovascular sequelae.
Myocardial dysfunction from agents not
associated with cumulative dose-related
cardiotoxicity (Type II agents)
A number of recently introduced cancer drugs cause cardiac dys-
function. Among them are the ‘targeted drugs’ against HER2/
erbB2- and vascular endothelial growth factor (VEGF) signalling
pathways (Table 1).23
Anti-HER2/erbB2 cancer drugs
Trastuzumab, a monoclonal antibody against the HER2/erbB2 re-
ceptor, in combination with chemotherapy substantially improves
overall survival of women with HER2-overexpressed breast
cancer and prolongs lives of patients with advanced gastric
cancer.24,25 It was the first type II agent to be studied broadly
with regard to cardiotoxicity, as the pivotal trial of trastuzumab
and anthracyclines found severe (NYHA III– IV) heart failure in
16% of patients. This incidence was much higher than that asso-
ciated with anthracycline treatment alone.26 One common
finding was that the concomitant use of trastuzumab with anthra-
cycline greatly increased the risk of cardiotoxicity. Consequently,
in all adjuvant breast cancer trials, trastuzumab was only used
after anthracyclines or with anthracycline-free chemotherapy
(Table 4). This lowered the incidence of severe heart failure to
0–3.9% and the rate of (asymptomatic) cardiac dysfunction to
7–34%. Importantly, patients in these trials were carefully selected
and were required to have a normal cardiac function (i.e. LVEF .
50–55%) and no significant pre-existing cardiac disease. The strin-
gent criteria for trastuzumab discontinuation were employed and
the withdrawal rate for cardiac dysfunction was as high as 16%.27
Further analysis of the time interval between the administration
of the anthracycline and the start of trastuzumab suggested that
a strong correlation in the concomitant administration was asso-
ciated with the highest reported incidence of cardiotoxicity,
while an interval of 3 months had an incidence that was almost
as low as was the incidence for those who had not been treated
with prior anthracyclines.28 This observation supported the
concept that trastuzumab may well act as a modulator of anthracy-
cline toxicity when administered during a period of myocyte vul-
nerability following anthracycline exposure (Figure 2).
Based on the observations in these trials, the following risk
factors for trastuzumab-associated cardiotoxicity were identified:
prior treatment with anthracycline chemotherapy; a borderline
lower limit of normal LVEF; prior treatment with anti-hypertensive
medication (for the lack of better definition this likely means pre-
existing arterial hypertension); advanced age; and a poorly under-
stood result found in one trial, a body mass index .25 kg/m2.
One common finding in these trials was that cardiac dysfunction
and heart failure occurred predominantly during the trastuzumab
treatment and was frequently reversible.29 However, only data
from about 5 years of the patient follow-up in the most prominent
trastuzumab trials are available, and longer-term surveillance is
needed. The cardiotoxicity of other anti-HER2 therapies, such as
the small molecule tyrosine kinase (TKI) inhibitor lapatinib, look
promising, however, but are still under investigation.30
Angiogenesis inhibitors (anti-vascular endothelial
growth factor) cancer drugs
Angiogenesis inhibitors that target VEGF with either antibodies
against VEGF (bevacizumab) or small molecule TKIs (sunitinib, sor-
afenib) prolong the lives of patients with a variety of solid tumours,
including metastatic colorectal, renal cell, hepatocelluar cancer, and
in GI stromal tumours.31,32 Vascular endothelial growth factor sig-
nalling also plays a role in myocardial and vascular homeostasis;
therefore, it is not surprising that these drugs can affect endothelial
cells, myocyte function, and metabolism.33
Bevacizumab was associated with cardiac dysfunction and heart
failure in up to 3.8% of patients, particularly when used together
with or after anthracyclines.34 Two recent meta-analysis, including
almost 7000 patients treated with sunitinib and 900 patients
treated with sorafenib, found a rate 4.1% for sunitinib-induced
heart failure and 1% for sorafenib-associated cardiac dysfunc-
tion.35,36 However, most of these data are from retrospective ana-
lyses; only few trials have evaluated cardiac function and heart
failure prospectively. Therefore, none of the data provided regard-
ing these agents should be considered definitive, and on-going
studies will investigate these effects in further detail.
The pathophysiology of anti-VEGF-induced cardiac dysfunction
and heart failure remains poorly understood. Sunitinib can
induce myocyte apoptosis in preclinical models: although, similar
to trastuzumab, cardiac biopsies from patients treated with this
agent show no major myocardial injury.23 Furthermore, all of
these agents can induce arterial hypertension, which may lead to
secondary heart failure in vulnerable patients.
These newer therapies should not yet be considered to have a
class effect on the heart; they have different mechanisms of onco-
logic efficacy, affect different metabolic pathways, have varying half-
lives, and are used in very different populations with differing
Table 4 Key facts: Type II drug-induced cardiotoxicity
Anti-HER2 and VEGF cardiotoxicity
Contractile dysfunction related to contractile element and
mitochondrial dysfunction
Mostly reversible
Risk factors
Anthracycline-related (when used with anthracyclines, all
anthracycline risk factors apply)
Lower pre-trastuzumab LV ejection fraction
Higher age
Pre-existing heart disease
Prevention
Decreased anthracycline burden
Increased time between anthracycline and trastuzumab?
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underlying predispositions for cardiac events. The mechanisms of
action vary between agents, as do their intended direct effects
on signalling within cells. Furthermore, yet to be studied indirect
effects may play a role in causing a variety of side effects and toxi-
cities to be seen in patients.23
BCR-ABL inhibitors
Imatinib and dasatinib are a small molecule TKIs used for the treat-
ment of chronic myelogenous leucemia (CML) and gastrointestinal
stromal tumours. Initial reports described severe heart failure in 10
CML patients treated with imatinib, but these findings could not be
confirmed in a large follow-up study.37,38 Isolated events of heart
failure were also reported in CML patients treated with dasatinib.39
Both compounds can also induce peripheral oedema, pleural and
pericardial effusion unrelated to heart failure—a condition that
has to be considered in the differential diagnosis.
Cardiovascular side effects beyond
cardiac dysfunction
Arterial hypertension
Cancer drug-induced arterial hypertension is now recognized as an
entity primarily associated with the use of angiogenesis inhibitors.40
On a dose-dependent basis, these drugs can worsen pre-existing
hypertension, or can cause de novo hypertension to develop. It is
difficult to determine the true incidence of anti-VEGF-induced
hypertension since various methods of blood pressure measure-
ment and definitions of hypertension have been used in trials. A
recent meta-analysis of studies with bevacizumab reported an inci-
dence of more than 23% for any grade hypertension, with almost
8% of patients experiencing severe hypertension.41 The incidence
of arterial hypertension associated with sunitinib and sorafenib
appear similar, and patients with pre-existing hypertension or
renal cell cancer have a higher risk.42,43
Hypertension can occur at any time during treatment: acute
complications include heart failure, proteinuria with renal throm-
botic microangiopathy, intracerebral haemorrhage, and, infre-
quently, reversible posterior leukoencephalopathy.40 It is unclear
if patients will encounter hypertension-induced long-term conse-
quences, such as cardiac and renal remodelling. For most patients,
the condition improves when angiogenesis inhibitor treatment is
held or stopped altogether, but in some instances profound hyper-
tension may persist and become life-threatening. Interestingly, in
the case of sunitinib, a correlation has been demonstrated
between oncologic efficacy and hypertension, suggesting that
blood pressure increases may be a marker for efficacy rather
than, or in addition to, a simple cardiac adverse event. Treatment
of sunitinib-associated hypertension has not been shown to impair
oncologic response, but further studies are needed. Such interac-
tions further support the need for careful monitoring and clinical
correlations between efficacy and adversity, and the need for a
broad onco-cardiologic perspective (Table 5).
The mechanism of angiogenesis inhibitor-induced hypertension
is not completely understood, but may be directly linked to the in-
hibition of VEGF-2 signalling.44 Vascular endothelial growth factor
signalling is important for proper endothelial function and nitric
oxide synthesis; inhibition impairs vasodilation.45 Other effects of
VEGF inhibition may include induction of endothelial cell death
and rarefaction of resistance vessels.40 Hypertension involves
mechanisms similar to those of tumour destruction, and therefore
may also be a marker for efficacy of angiogenesis inhibitors.46
Vasospastic and thromboembolic
ischaemia associated with anti-cancer
treatment
Among agents associated with coronary artery spasm, the pyrimi-
dine analogues 5-fluorouracil (5-FU) and its oral pre-drug capecita-
bine are the most common.47–49 Underlying coronary artery
disease has been associated with an increased incidence of coron-
ary artery spasm, although there are patients with normal coron-
aries that have had spasms while being treated with these drugs.
Rhythm disturbances accompanying ischaemic events have been
reported as well. Ischaemia most typically occurs after the
second or third administration of these antimetabolites. Nitrogly-
cerin and calcium-channel blockers are often effective for the
treatment and prevention of ischaemia. In rare instances, progres-
sion to myocardial infarction has been reported.
Thromboembolic events
Patients with malignancies are in a hypercoagulable state and con-
ventional chemotherapeutics, signalling inhibitors, and endocrine
cancer therapies can further increase a patient’s risk of experien-
cing a venous or arterial thromboembolic event (VTE and ATE, re-
spectively).50 For example, cisplatin was found to cause VTE in up
to 18% of patients; a direct endothelial-toxic effect and changes in
the coagulation system are likely responsible for this side effect.51
Patients treated with bevacizumab also experienced a higher rate
of thromboembolic events compared with patients treated with
chemotherapy alone; elderly patients with cardiovascular risk
factors were shown to have the highest rates of all.52,53 Similar
Table 5 Key facts: cancer drug-induced arterial
hypertension
Arterial hypertension
Primarily with angiogenesis inhibitors
Mechanism: endothelial dysfunction
Risk factors
Pre-existing hypertension
Consequences
Acute heart failure, generally reversible
Proteinuria, renal failure
Intracerebral haemorrhages
Reversible posterior leuckoencephalopathy
Prevention
Optimal treatment of per-existing high blood pressure
Treatment
No trial-based evidence
Use common antihypertensives
Caution with non-dihydropyridine calcium channel blockers
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risks for ATEs have been reported for sunitinib and sorafenib.54
Increased incidences of thromboembolic events have also been
found with hormonal therapy, such as tamoxifen, which is now
an integral part of many breast cancer regimens.55
Prophylactic anticoagulation is only recommended in high-risk
cancer patients who are hospitalized or undergo surgery and in
selected patients with multiple myeloma.56 Several trials are cur-
rently investigating the potential role of prophylactic low molecular
heparin. There are no clear guidelines for the prevention of ATEs
in the setting of cancer therapy; only evidence-based guidelines
used for patients without cancer should be used until studies are
conducted. It is unknown whether cancer patients have an
altered risk of coronary thrombosis after stenting.
Dysrhythmia and QT prolongation
Rhythm disturbances associated with anti-cancer treatment are
typically transient and not especially troubling. They occur most
commonly as a consequence of metabolic changes and generally
resolve after electrolyte homeostasis is re-established. Anthracy-
clines, for example, are associated with supraventricular arrhyth-
mias and ventricular ectopy during and shortly after
administration, a condition that usually resolves without sequelae
after heart rate control. Similarly, taxanes can induce sinus brady-
cardia during treatment, but this is seldom severe and intervention
is rarely warranted. Some rhythm disturbances are associated with
structural changes within the heart, as may be seen with tumour
invasion or as a manifestation of chronic anthracycline
cardiomyopathy.
QT prolongation is associated with a number of anti-cancer
drugs and may constitute a significant problem. Many cancer
patients have multiple comorbidities, including diarrhea- and
vomiting-induced electrolyte disturbances, and concomitant medi-
cations such as psychotropic medications and anti-emetics that
may further prolong the QT interval. Among specific anti-cancer
treatments, arsenic trioxide, typically used to treat leucemia, has
received considerable attention in this regard since it may
prolong the QT interval in up to 40% of treated patients and has
a significant risk of Torsades de Pontes.57 Several of the newer sig-
nalling inhibitors also prolong the QT interval, although Torsades is
a relatively infrequent event. Vandetanib, an orally available mul-
tiple target TKI for the treatment of thyroid cancer, has been asso-
ciated with a moderate risk of QT prolongation.58 Nilotinib and
dasatinib can also prolong the QT interval, although symptomatic
manifestations were recorded in only a few patients.59 In patients
treated with lapatinib or sunitinib, QT prolongation was rarely
observed.
Diagnostic considerations
While cardiovascular side effects such as arterial hypertension,
myocardial ischaemia, dysrhythmia, and thrombosis can be
readily diagnosed, the assessment of cardiac dysfunction and its
prognosis is more challenging. Most currently used methods asses-
sing cardiac function cannot differentiate between irreversible
(Type I) and reversible (Type II) cardiotoxicity, and may mislead
physicians to stop potentially lifesaving cancer therapy
unnecessarily.
Historically, patients with anthracycline-induced cardiotoxicity
were evaluated with right-ventricular endomyocardial biopsies;
morphologic changes correlated with the cumulative dose
applied and (to a limited extent) with the onset of heart
failure.60,61 However, correlation of biopsy scores with non-
invasively assessed LVEFs was poor.9 More recently, the predictive
value of serial LVEF evaluation by either echocardiography or mul-
tiple gated acquisition (MUGA) scans in adult cancer patients was
assessed in several studies. While some investigators found an
early drop in LVEF to be predictive for later onset of heart
failure, others did not.11,62,63
Despite these limitations, non-invasive imaging is now common-
ly used in cancer patients for initial screening and detection of
cardiac dysfunction during cancer therapy.64 Although these
methods of evaluating patients for cardiotoxicity are useful, and
should be applied for any patient at risk for cardiac dysfunction,
they have limited accuracy for risk stratification. Newer echocar-
diographic modalities, such as tissue Doppler and strain techniques,
were shown to detect anthracycline-induced cardiac dysfunction
earlier than conventional echocardiography, but it is not known
if these methods have a higher specificity to detect Type I cardio-
toxicity.65 Other imaging methodologies that can assess myocardial
tissue structure may prove superior to echocardiography and
MUGA; initial data with cardiac magnetic resonance look
promising.66
The limitations of cardiac imaging to risk stratify cancer patients
with cardiac dysfunction may be resolved by the use of cardiac bio-
markers. These biomarkers should readily identify myocardial and
endothelial injury; these would be particularly useful if they predict
cardiovascular outcome for patients.
Early data assessing brain natriuretic peptide (BNP) in patients
treated with anthracyclines showed that most patients experience
a transient increase in this biomarker and the predictive value for
long-term cardiotoxicity may be limited when used alone.67,68 Tro-
ponins I and T have been shown to be predictive markers for late
anthracycline cardiotoxicity in children.69 Furthermore, Cardinale
and colleagues successfully used troponin to identify anthracycline-
treated patients who would benefit from treatment with an ACE
inhibitor.70 Despite these promising results, the assessment of
cardiac biomarkers is not being done routinely in patients undergo-
ing potentially cardiotoxic cancer treatment and there is a need for
large, multicentre trials to evaluate the role of biomarkers in this
population.
Key clinical points
Cancer drugs inducing cardiac
dysfunction and heart failure
Because of the side effects, and the availability of alternative, less
cardiotoxic regimens, treatment with anthracycline has declined
over the last decade; also, the exceedingly high cumulative doses
used previously are employed much less frequently now. Notwith-
standing these considerations, anthracyclines are still widely used,
and it is likely that these agents will remain part of our therapeutic
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armamentarium for some time to come. Evidence-based algo-
rithms for pre-treatment evaluation and surveillance of adult
patients during and following cancer treatment do not exist; they
are unlikely to evolve, in view of the diversity of both treated
populations and variety of regimens employed. Additionally, pro-
spective long-term studies focusing on late cardiotoxicity are
few. Despite these limitations, we present our approach based
on data derived from experience with our particular patient
population.
Prior to anthracycline treatment, we obtain a comprehensive
medical history and complete a physical examination, supplemen-
ted by an electrocardiogram, baseline measurement of LVEF, and
cardiac biomarkers troponin and BNP. This information helps
stratify patients at low, intermediate, or high risk for cardiotoxi-
city, each of which should be treated differently. Patients
without significant cardiac history who are under age 65, and
have normal LVEF and cardiac biomarkers should be considered
low risk. Such patients will usually tolerate up to six cycles
of an anthracycline-containing regimen without unacceptable
cardiac risk. If any exams prior to chemotherapy are indicative
of pre-existing or active cardiovascular disease, the patients
would be considered either intermediate or high risk for cardio-
toxicity. In these cases, a dialogue with the treating oncologist in
an attempt to balance oncologic benefit with anticipated cardio-
vascular risk is warranted. A less cardiotoxic regimen might be
particularly important if treatment with a signalling inhibitor is
planned after chemotherapy.
We re-assess cardiac function of all patients after four cycles of
chemotherapy to identify asymptomatic patients who are experi-
encing increased cardiac damage; if LVEF has decreased by either
15 percentage points, or 10 percentage points to a value below
50 and a repeat assessment after 3 weeks confirms the finding;
or if troponin or BNP are elevated, we discuss alternative che-
motherapeutic regimens with the oncologist, as continuing treat-
ment with an anthracycline carries increased risk for
cardiotoxicity. The parameters suggested here represent a
balance between over-inclusiveness that may result in increased
monitoring and under-inclusiveness that may miss potentially im-
portant early signs of cardiac damage. They proved reasonable in
many recent cancer trials testing potentially cardiotoxic drugs,
but are not yet universally accepted. Additionally, considerable
variation exists in the measurement of LVEF in that factors unre-
lated to the cancer drug may have a significant impact on cardiac
function. As discussed earlier, newer imaging modalities may be
more helpful in detecting early signs of cardiotoxicity, but these
methods have not yet been shown to predict long-term prognosis
of patients. Regardless of the technique employed, elevated
concern at the time of the cardiac re-assessment moves such initially
low-risk patients into the intermediate risk group (Figure 3 for
specific recommendations).
Treatment of anthracycline-induced cardiac dysfunction war-
rants aggressive intervention with standard modalities consistent
with treatments for other forms of heart failure. When the
underlying malignancy is well controlled and life-expectancy
does not preclude aggressive interventions, even the use of
devices and in extreme instances, cardiac transplantation may
be considered.71 No clear consensus regarding the duration of
the follow-up for asymptomatic patients exists. Nevertheless,
studies of patients undertaken years after their treatment with
anthracycline-based regimens have shown cardiac abnormalities;
additionally, patients may develop frank heart failure that may
be due to intercurrent stress or injury, making some level of
follow-up mandatory. A reasonable schedule might include a
measurement of systolic function at 6 months after conclusion
of treatment, annually for 2 or 3 years thereafter, and then at
3–5-year intervals for life. Any cardiovascular occurrences
during the follow-up warrant more stringent surveillance. High-
risk patients, e.g. those with underlying cardiovascular disease,
or those who have received .300 mg/m2 of doxorubicin or
equivalent, may be monitored more frequently, although data
to support an outcome advantage resulting from such monitor-
ing has not been reported.
Optimal surveillance for patients treated with Type II agents is
not well established. Patients who have received both anthracy-
clines and newer signalling inhibitors who develop cardiac failure
should be treated and monitored as suggested above. Those
who develop cardiac dysfunction during or following treatment
with type II agents in the absence of anthracyclines can be
observed if they remain asymptomatic and LVEF remains .40%
(Figure 3). Persistently low or further declines in LVEF or develop-
ment of symptoms should trigger discussion of risk and benefit
with the treating oncologist, as well as consideration for pharmaco-
logic cardiac treatment. Duration of cardiac therapy has not been
studied sufficiently to warrant guidance; some patients have been
successfully discontinued 6 months following the recovery of
LVEF into the normal range, with no subsequent dysfunction.
Most patients tolerate anti-cancer therapy after treatment for
the cardiac dysfunction, but isolated instances of recurrent symp-
tomatic dysfunction that require cessation of anti-cancer therapy
have been reported. Reintroduction of anti-cancer therapy is a pri-
ority, when possible, even if cardiac therapy must be continued
throughout.
Cancer drugs inducing arterial
hypertension
Careful monitoring and treatment of blood pressure throughout
therapy with angiogenesis inhibitors is important. There are no
evidence-based therapeutic guidelines available for patients ex-
periencing elevated blood pressures; we have successfully used
ACE inhibitors, beta-blockers, and dihydropyridine calcium
channel blockers. Non-dihydropyridine calcium channel blockers
(verapamil and diltiazem) should only be used with caution,
since they are cytochrome P450 3A4 inhibitors and can interact
with the metabolism of several cancer drugs. Some have
advised that diuretics should not be used as first-line therapy
since small molecule VEGF TKIs sometimes lead to severe diar-
rhea and potential dehydration. In general, angiogenesis-inhibitor
induced hypertension is manageable, and we only stop treatment
with VEGF inhibitors for severe hypertension (Figure 3), or if the
patient experiences additional hypertension-related complications.
We agree with recently published recommendations of the US
National Cancer Institute to maintain patients’ blood pressure
at lower than 140/90 mmHg.40
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Figure 3 Therapeutic considerations for patients under active cancer treatment with cardiovascular side effects. aHypertension grade according to European Society of Hypertension; LVEF, left
ventricular ejection fraction; NYHA, New York Heart Association Classification; CT, cancer therapy; LVD, left ventricular dysfunction; HF, heart failure; HTN, hypertension.
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Summary and conclusions
The recognition of cardiac problems related to the treatment of
cancer is complex. The heterogeneity of the population makes
comparison between and among groups difficult. Studies on suffi-
ciently large populations are frequently not available, and the
number of new agents used in the treatment of some diseases
makes evaluation of large cohorts impossible. Some reported
results are therefore fragmented, and prospective data on long-
term survival, treatment strategies, and monitoring represents all
too often expert opinion rather than firm and established data-
derived certainty. Identifying patients who are at increased risk
for cardiovascular problems associated with the cancer treatment,
or who develop side effects following treatment is a major compo-
nent of an evolving area often referred to cardio-oncology.
Working together with oncologists, cardiologists can offer vital
support to those who are the primarily clinicians treating cancer
patients so that therapy can be optimized; the goal should be to
maximize meaningful survival. Judicious scrutiny of the needs of
these complex patients requires careful balance: excessive
concern regarding potentially reversible cardiac issues may com-
promise the administration of highly beneficial anti-cancer therap-
ies, while under-appreciation of cardiac risk may result in life-long
cardiac concerns for a patient who has been cured of their cancer.
Knowledge of the cardiac effects of anti-cancer agents balanced
with knowledge regarding the natural history of the malignancy
and the likelihood of tumour response offers such patients the
greatest chance for long-term disease-free survival.
Through observation of side effects caused by newly developed
cancer therapeutics, some cardiovascular signalling pathways have
become more clearly understood. It is postulated that the Neure-
gulin/erbB2/HER2 signalling pathway, the target of several
anti-cancer therapies, plays an important role in cardiovascular
homeostasis, and studies are being conducted to evaluate the
stimulation of this pathway to treat heart failure patients.72
Signalling inhibitors, chemotherapeutics, and combinations
thereof are the subject of intense research and ongoing clinical
trials in oncology. New cancer therapeutics will continue to
target signalling cascades that may also be important for the sur-
vival and homeostasis of cardiovascular tissue.73 Cardiovascular
side effects from these agents should be expected because of
their direct effect on signalling or the potential of additional non-
targeted inhibitory effects.23
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